TFRC and breast carcinoma: According to studies, the expression of the transferrin receptor (TfR) is up to five times higher in cancerous tissue than in healthy tissue (31), DOX-Tf compound should be able to increase the intracellular concentration of medicines in breast cancer cells, assisting in the treatment of chemoresistance (32).